2011
Secondary preventive medication persistence and adherence 1 year after stroke
Bushnell C, Olson D, Zhao X, Pan W, Zimmer L, Goldstein L, Alberts M, Fagan S, Fonarow G, Johnston S, Kidwell C, LaBresh K, Ovbiagele B, Schwamm L, Peterson E. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology 2011, 77: 1182-1190. PMID: 21900638, PMCID: PMC3265047, DOI: 10.1212/wnl.0b013e31822f0423.Peer-Reviewed Original ResearchConceptsSecondary prevention medicationsPrevention medicationsSystem-level factorsMedication persistenceHospital dischargeIndependent predictorsIschemic stroke Longitudinal (AVAIL) registryGuidelines-Stroke programSecondary preventive medicationsUse of warfarinPrimary care providersAmerican Heart AssociationHealth care providers' instructionsLong-term useHospitalization dischargeModifiable patientDiabetes medicationsIschemic strokePreventive medicationsStroke patientsHeart AssociationCare providersMedicationsSide effectsPatients
2010
Persistence With Stroke Prevention Medications 3 Months After Hospitalization
Bushnell C, Zimmer L, Pan W, Olson D, Zhao X, Meteleva T, Schwamm L, Ovbiagele B, Williams L, LaBresh K, Peterson E. Persistence With Stroke Prevention Medications 3 Months After Hospitalization. JAMA Neurology 2010, 67: 1456-1463. PMID: 20697032, PMCID: PMC10197116, DOI: 10.1001/archneurol.2010.190.Peer-Reviewed Original ResearchConceptsSecondary prevention medicationsPrevention medicationsLong-term secondary stroke preventionGuidelines-Stroke programStroke prevention medicationsLipid-lowering therapyPatients 18 yearsSecondary stroke preventionTransient ischemic attackMonths of hospitalizationObservational cohort designAmerican Heart AssociationMedication-taking behaviorCombination of patientQuality of lifeSystem-level factorsAntihypertensive therapyIschemic attackAntiplatelet therapyDiabetes medicationsMedication classesStroke preventionAcute strokeHospital dischargeIschemic stroke
2009
The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics
Bushnell C, Zimmer L, Schwamm L, Goldstein L, Clapp-Channing N, Harding T, Drew L, Zhao X, Peterson E. The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics. American Heart Journal 2009, 157: 428-435.e2. PMID: 19249411, DOI: 10.1016/j.ahj.2008.11.002.Peer-Reviewed Original ResearchConceptsIschemic stroke Longitudinal (AVAIL) registryTransient ischemic attackIschemic attackRecurrent strokePrevention medicationsLongitudinal registryAdherence evaluationSecondary preventive therapyBaseline patient characteristicsModified Rankin scoreSecondary prevention measuresMedication-taking behaviorSystem-level barriersLevel of adherenceFuture strokeCardiovascular eventsRankin scoreVascular eventsAcute hospitalizationHospital dischargePatient characteristicsPreventive therapySecondary outcomesMedication usePrimary outcome